- Home
- FG vs NUVL Comparison
FG vs NUVL Comparison
Compare FG & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FG
- NUVL
- Stock Information
- Founded
- FG 1959
- NUVL 2017
- Country
- FG United States
- NUVL United States
- Employees
- FG N/A
- NUVL N/A
- Industry
- FG Life Insurance
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- FG Finance
- NUVL Health Care
- Exchange
- FG Nasdaq
- NUVL Nasdaq
- Market Cap
- FG 5.3B
- NUVL 5.5B
- IPO Year
- FG N/A
- NUVL 2021
- Fundamental
- Price
- FG $40.12
- NUVL $79.49
- Analyst Decision
- FG Hold
- NUVL Strong Buy
- Analyst Count
- FG 2
- NUVL 11
- Target Price
- FG $46.50
- NUVL $112.36
- AVG Volume (30 Days)
- FG 78.3K
- NUVL 420.4K
- Earning Date
- FG 02-20-2025
- NUVL 03-04-2025
- Dividend Yield
- FG 2.19%
- NUVL N/A
- EPS Growth
- FG N/A
- NUVL N/A
- EPS
- FG 4.88
- NUVL N/A
- Revenue
- FG $5,744,000,000.00
- NUVL N/A
- Revenue This Year
- FG N/A
- NUVL N/A
- Revenue Next Year
- FG N/A
- NUVL N/A
- P/E Ratio
- FG $8.23
- NUVL N/A
- Revenue Growth
- FG 26.60
- NUVL N/A
- 52 Week Low
- FG $34.90
- NUVL $61.80
- 52 Week High
- FG $50.75
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- FG 34.11
- NUVL 43.83
- Support Level
- FG $44.81
- NUVL $77.84
- Resistance Level
- FG $47.76
- NUVL $85.21
- Average True Range (ATR)
- FG 1.61
- NUVL 3.78
- MACD
- FG -0.46
- NUVL -0.46
- Stochastic Oscillator
- FG 5.68
- NUVL 12.08
About FG F&G Annuities & Life Inc.
F&G Annuities & Life Inc is a provider of insurance solutions serving retail annuity and life customers as well as institutional clients. Through its insurance subsidiaries, including FGL Insurance and Fidelity & Guaranty Life Insurance Company of New York it markets a broad portfolio of deferred annuities (fixed indexed annuities (FIAs) and multi-year guarantee annuities (MYGAs) or other fixed rate annuities), immediate annuities, indexed universal life (IUL) insurance, funding agreements through funding agreement-backed notes (FABN) issuances and the Federal Home Loan Bank of Atlanta (FHLB)) and pension risk transfer (PRT) solutions.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.